INC Research announced the launch of Psychiatry Catalyst Site Network as part of its Catalyst program introduced in 2016 to collaborate with clinical research sites worldwide. The ultimate goal of the program is to enhance patient focus and optimize study delivery to drive improved predictability and increased efficiency for customers. INC selected 32 clinical research sites to participate in the initial launch of the Psychiatry Catalyst Site Network, which was formed to respond to the rapid growth and pipeline of psychiatric studies. The Psychiatry Catalyst Site Network joins INC’s existing networks in place in support of Oncology and Vaccine clinical research.
“Demonstrating our continued focus on strong site collaboration to improve study delivery, INC Research has expanded its Catalyst program into the Central Nervous System (CNS) and specifically, psychiatry clinical research,” Clare Grace, PhD, Vice President, Site and Patient Access, INC Research said. “Our Catalyst initiative aligns with INC’s deep therapeutic focus and supports the delivery of high-quality, actionable data to advance new therapies. Our expansion of the program in response to the growing number of psychiatric studies, recognized as among the more complex therapeutic areas in clinical research, will leverage expert insights to further enhance clinical development and accelerate new therapies to market in this critical area.”
Sites selected for the Psychiatric Catalyst Site network will work with each other and with INC Research to deliver studies more quickly and more predictably. Through both the Protocol Review SAG and the Psychiatry Catalyst Site Network, INC will further streamline processes to improve the patient experience while ultimately accelerating new therapies to market for customers.
Participation in INC’s Catalyst Psychiatry Site Network is by invitation only with membership initially focused on the United States. Members will have the opportunity to participate in an increased volume of psychiatric-related trials, with dedicated relationship managers supporting each site and facilitating better alignment of protocols to their interests and expertise. Membership will be reviewed regularly to ensure the network is meeting customer needs. INC Research expects to continue the expansion of its Catalyst program to include additional therapeutic areas, indications and regions.
Over the past five years, INC Research has conducted more than 115 psychiatry studies across all phases of development, including studies that address conditions like schizophrenia, suicidality, depression and dementia.